Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh

PFIZER INC

Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.
Plus up to $20.65/sh in contingent value rights tied to three FDA/clinical milestones.
Milestones: Phase 3 start for MET-097i+MET-233i combo ($4.60/sh), FDA nod for monthly MET-097i ($6.40/sh), FDA nod for combo ($9.65/sh).
Acquisition aimed at bolstering Pfizer's obesity pipeline with GLP-1 receptor antagonist + amylin analog.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.